This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
by Zacks Equity Research
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
NVSPositive Net Change AMGNNegative Net Change IONSNegative Net Change
biotechs
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
by Zacks Equity Research
AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.
AZNPositive Net Change NVSPositive Net Change PFENegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
by Ekta Bagri
Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
BMYNegative Net Change CYTKNegative Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
by Zacks Equity Research
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
SMMTNegative Net Change MRKNegative Net Change ALDXNegative Net Change ACIUNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
by Zacks Equity Research
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
IONSNegative Net Change ACIUNegative Net Change IOVANegative Net Change
biotechs medical
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
by Sundeep Ganoria
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
BMRNPositive Net Change ASNDNegative Net Change BBIONegative Net Change
biotechs medical
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
by Sundeep Ganoria
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
MRNANegative Net Change SNYNegative Net Change GSKNegative Net Change MRKNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
by Zacks Equity Research
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
KYMRPositive Net Change ARVNNegative Net Change NRIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
by Zacks Equity Research
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
RARENegative Net Change ALDXNegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
by Ahan Chakraborty
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
RXRXNegative Net Change SDGRNegative Net Change RLAYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals